Scholar Rock stock downgraded at Barclays (SRRK:NASDAQ)

Scholar Rock received FDA approval for Isembyld, a drug targeting muscle loss in spinal muscular atrophy (SMA). The approval follows successful clinical trials showing improved motor skills in patients. The drug is approved for use with existing SMA therapies. Scholar Rock, valued at $6.8B, addressed manufacturing issues before resubmission. Pricing details are pending.

Barclays downgraded Scholar Rock (SRRK) to Equal Weight, raising its price target to $58. The move follows FDA approval of Isembyld, but Barclays cites valuation concerns. SRRK's P/S ratio is 30.4x, and its GF Score is 29/100, indicating financial challenges. Insider activity shows balanced buying and selling.

Barclays downgraded Scholar Rock (SRRK) to Equalweight, raising its price target to $58. The move follows the FDA approval of Isembyld (apitegromab) for spinal muscular atrophy. Analysts cite balanced risk-reward and commercial execution as key factors. SRRK stock is down 9.7% over the past week, trading at $51.85. Other analysts maintain Buy ratings with higher price targets, citing potential rapid uptake.

Raymond James increased its price target on Scholar Rock (SRRK) to $72 from $65, maintaining a Strong Buy rating. The FDA approval of ISEMBYLD for SMA could lead to a quick U.S. launch, with potential $2.2B revenue by 2035, according to the analyst.

Elmet Group (ELMT) surged 35.55% after a $450M DoD investment. Baldwin Insurance (BWIN) rose 7.66% on a $7.7B take-private deal. Scholar Rock (SRRK) fell 4.07% despite FDA approval. RUM Group (RUM) gained 15.41% on a $13.7B GPU deal with Anthropic.

Scholar Rock (SRRK) shares rose 9.1% to $60.45 after FDA approved ISEMBYLD for spinal muscular atrophy. The treatment targets adults and children aged 2+ on SMN2-targeted therapy. Analysts raised price targets, with Truist, Raymond James, and Citi citing strong potential. SRRK has $492M in cash and prepares for commercial launch.